Synonyms: GS-5885 | GS5885 | Harvoni® (ledipasvir + sofosbuvir)
ledipasvir is an approved drug (EMA & FDA (2014))
Compound class:
Synthetic organic
Comment: Ledipasvir is an orally available, direct-acting inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex [1].
|
|
References |
1. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H et al.. (2012)
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol, 57 (1): 24-31. [PMID:22314425] |